BofA raised the firm’s price target on Gilead (GILD) to $162 from $154 and keeps a Buy rating on the shares. Strong Q4 dynamics give the firm confidence in 2026 growth, the analyst tells investors in a post-earnings note. The firm no longer models Yeztugo cannibalization of Descovy sales in 2026, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD: